10-K annual report · filed Feb 25, 2016

Teleflex Inc (TFX) FY2015 10-K Annual Report

Short answer

Teleflex Inc (TFX) filed its fiscal 2015 10-K annual report with the SEC on Feb 25, 2016.

  • Top risk flagged: FDA medical-device regulation: noncompliance could trigger manufacturing shutdowns, recalls, civil penalties, or Medicare and Medicaid exclusion

Teleflex Inc FY2015 10-K analysis

AI summary of each section, grounded in the filing text

Business Overview

  • Global medical-device model centered on single-use products for hospital critical care and surgical procedures
  • Six reportable segments after April 2015 reorganization, separating Anesthesia North America from Respiratory North America
  • Percuvance percutaneous surgical system received 510(k) clearance, with controlled U.S. and European launch
  • 2015 acquisitions expanded anesthesia, surgical, vascular, Asia and OEM portfolios, including balloons and balloon catheters
  • R&D spending $52.1 million, down from $61.0 million in 2014, with approximately 12,200 employees worldwide

Management Discussion & Analysis

  • Revenue $1,809.7M, down $30.1M or 1.6% YoY, primarily from $129.1M unfavorable currency impact
  • Gross margin 52.2% vs 51.2%; SG&A margin 31.4% vs 31.5%; effective tax rate 3.2% vs 13.0%
  • Best segment: Vascular North America revenue $334.9M, operating profit $73.3M, up 36.2%; worst: EMEA revenue $514.5M, down 13.3%
  • Operating cash flow $303.4M; capex $61.4M; acquisitions $93.8M; dividends $56.5M
  • Outlook: restructuring charges $34M to $44M, annual savings $12M to $16M; risks from currency, European collections and Asian pricing controls

Risk Factors

  • FDA medical-device regulation: noncompliance could trigger manufacturing shutdowns, recalls, civil penalties, or Medicare and Medicaid exclusion
  • European exposure: $62.3M receivables in Italy, Spain, Portugal, and Greece amid constrained credit markets
  • Manufacturing concentration: key products rely on single manufacturing or distribution locations with limited alternatives
  • Competitive disruption: rivals may introduce devices with better clinical outcomes, features, or economic value
  • Leverage: $1,066M total indebtedness as of December 31, 2015, constraining cash flow and financial flexibility

Generated from the filing text; verify against the original. How to read a 10-K

Other Teleflex Inc annual reports

Ask about this 10-K

Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.